Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.

Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A.

J Thorac Oncol. 2018 Jun;13(6):748-751. doi: 10.1016/j.jtho.2018.02.013. No abstract available.

PMID:
29793646
2.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Apr 12. doi: 10.1158/1078-0432.CCR-18-0042. [Epub ahead of print]

PMID:
29650751
3.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.

Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, Schenkel C, Miller B, Dunleavy K, Wang J, Zeldis J, Little RF.

J Clin Oncol. 2017 Nov 20;35(33):3774-3780. doi: 10.1200/JCO.2017.73.7338. Epub 2017 Oct 2.

4.

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL.

J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.

PMID:
28968170
5.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL.

Gynecol Oncol. 2017 Oct;147(1):3-10. doi: 10.1016/j.ygyno.2017.08.012. Epub 2017 Aug 24. Review. No abstract available.

PMID:
28844539
6.

Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials.

Beaver JA, Ison G, Pazdur R.

N Engl J Med. 2017 Apr 20;376(16):1504-1505. doi: 10.1056/NEJMp1615879. No abstract available.

PMID:
28423289
7.

Selective anti-scatter grid removal during coronary angiography and PCI: a simple and safe technique for radiation reduction.

Roy JR, Sun P, Ison G, Prasan AM, Ford T, Hopkins A, Ramsay DR, Weaver JC.

Int J Cardiovasc Imaging. 2017 Jun;33(6):771-778. doi: 10.1007/s10554-017-1067-5. Epub 2017 Jan 24.

PMID:
28120155
8.

Real-time colour pictorial radiation monitoring during coronary angiography: effect on patient peak skin and total dose during coronary angiography.

Wilson SM, Prasan AM, Virdi A, Lassere M, Ison G, Ramsay DR, Weaver JC.

EuroIntervention. 2016 Oct 10;12(8):e939-e947. doi: 10.4244/EIJV12I8A156.

9.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.

Ison G, Beaver JA, McGuinn WD Jr, Palmby TR, Dinin J, Charlab R, Marathe A, Jin R, Liu Q, Chen XH, Ysern X, Stephens O, Bai G, Wang Y, Dorff SE, Cheng J, Tang S, Sridhara R, Pierce W, McKee AE, Ibrahim A, Kim G, Pazdur R.

Clin Cancer Res. 2016 Sep 15;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. Epub 2016 Jul 11. Review.

10.

Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application.

Kim ES, Atlas J, Ison G, Ersek JL.

Am Soc Clin Oncol Educ Book. 2016;35:83-90. doi: 10.14694/EDBK_155880.

11.

Successes and Challenges of PARP Inhibitors in Cancer Therapy.

Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.

Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015. Review. No abstract available.

12.

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.

Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17. Review.

13.

Radiation exposure during elective coronary angioplasty: the effect of flat-panel detection.

Prasan AM, Ison G, Rees DM.

Heart Lung Circ. 2008 Jun;17(3):215-9. doi: 10.1016/j.hlc.2007.10.009. Epub 2008 Jan 31.

PMID:
18242132

Supplemental Content

Support Center